We have characterized the biodistribution and dosimetry of 18 F-39-F-6-OH-BTA1 ( 18 F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects. Methods: Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of 18 F-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined. Results: No adverse events or clinically significant changes were observed. 18 F-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 mGy/ MBq, respectively). The mean effective dose was 33.8 6 3.4 mSv/MBq, a dose comparable to that of many other 18 F-labeled radiopharmaceuticals. Conclusion: The estimated effective dose of 18 F-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.

No abstract

No abstract

Vessels Revim.Y Doud eompl.eted their. evaluation at the mdiation ~ • to the Ki\PI,.,.~4 cubtm steel tbimbleo The Board decided that 1 t. W&S aafe to extend the o:pemting life of the th.imble :r&om 9 to l6)!rR cycles; subject to review if~ exten<1ed .low tem.pemtwre operation OCCUI'So •TbirB ~ s~izes the ds.ta. 8Z!d eva.lua'tion Wich ..